Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
UnitedHealthcare BALANCE Model GLP-1: What UHC Members Need to Know in 2026
By The RX Index Editorial Team · Last verified:
The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. This page is informational and is not medical or insurance advice.
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
If you have UnitedHealthcare and you’ve been searching the UnitedHealthcare BALANCE Model GLP-1 rules, here’s the part almost nobody says plainly: BALANCE isn’t a UnitedHealthcare program. It’s a federal program run by Medicare and Medicaid. And for many UnitedHealthcare members on Medicare, the thing that may finally lower your GLP-1 cost in 2026 isn’t BALANCE at all — it’s a separate Medicare pilot called the Medicare GLP-1 Bridge, which starts July 1, 2026 and charges a flat $50 a month if you qualify.
If you’re on a UnitedHealthcare commercial or employer plan, the Bridge doesn’t apply to you, and BALANCE won’t change your employer’s drug benefit — your plan’s own coverage and prior authorization rules still decide everything.
So which of these actually applies to you? It comes down to one thing: what kind of UnitedHealthcare plan you have. There are four very different lanes here, and people get denied, overpay, or wait around for the wrong thing because they’re standing in the wrong one. The table below tells you your lane in about ten seconds.
Which UnitedHealthcare GLP-1 lane are you in?
Your GLP-1 path depends on your UHC plan type — not on a single yes or no. UHC Medicare members look at the Medicare GLP-1 Bridge. UHC commercial and employer members look at their plan’s prior authorization rules. UHC Medicaid members depend on their state. Find your row, then read the matching section below.
| If you have… | Your likely lane | Your first move |
|---|---|---|
| UHC Medicare (Part D, or Medicare Advantage with drug coverage) — GLP-1 for weight loss | Medicare GLP-1 Bridge ($50/mo, starts July 1, 2026) | Check the Bridge eligibility tiers, then ask your prescriber |
| UHC Medicare — GLP-1 for diabetes, sleep apnea, heart risk, or liver disease | Your plan’s regular Part D coverage | Check your drug list and the right approval pathway |
| UHC commercial or employer plan | Your plan’s own coverage + prior authorization | Confirm your employer actually covers weight-loss drugs |
| UHC Medicaid / Community Plan | Your state’s Medicaid rules (plus BALANCE if your state joins) | Check your state’s GLP-1 policy |
| Not sure which you have | Start with the next section | Read “How do I know which plan I have?” below |
A quick word on the terminology. Prior authorization means your plan has to approve a drug before it pays — your doctor sends paperwork, the plan says yes or no. A formulary is your plan’s list of covered drugs. Part D is Medicare’s prescription-drug coverage. Keep those three handy and the rest of this page gets a lot easier.
How do I know if my UnitedHealthcare plan is Medicare, commercial, or Medicaid?
Look at your member card and your online account for a few key words. The same UnitedHealthcare logo sits on very different kinds of coverage, and this whole page only works if you pick the right lane first.
Here’s what to look for:
- Medicare: “Medicare Advantage,” “MA-PD,” “Part D,” “AARP Medicare Complete,” “Dual Complete,” or “PDP.”
- Commercial / job-based: “Employer,” “Group,” “Choice Plus,” “Options PPO,” or a plan you got through work or the marketplace.
- Medicaid: “Community Plan,” “Medicaid,” “Dual Complete,” or your state’s Medicaid name (like MassHealth).
- Pharmacy manager: Many UHC plans list OptumRx — that’s the company that handles your prescription coverage and prior authorizations.
Still not sure? Call the member number on the back of your card and ask one simple question: “Is my plan Medicare, commercial, employer, or Medicaid?” That single answer tells you which section below is yours.
The UnitedHealthcare GLP-1 Coverage Lane Matrix
This is the one table that pulls the Medicare Bridge, the BALANCE Model, UnitedHealthcare’s commercial drug policy, and UHC’s Medicaid rules into a single UHC-specific view. It shows which program controls your coverage, what you’d pay, who handles the approval, the paperwork mistake that trips people up, and your best next step. No single source — not CMS, not UHC, not the news — puts the UnitedHealthcare answer in one place like this.
| Your UHC situation | Which lane controls it | Drugs in play | What you’d pay | Who approves it | Paperwork trap | Do this now |
|---|---|---|---|---|---|---|
| UHC Medicare, GLP-1 for weight management | Medicare GLP-1 Bridge | Wegovy (injection/tablet), Zepbound KwikPen only, Foundayo | $50/mo if eligible | CMS’s central processor (Humana) — not UHC | Listing your current weight instead of your weight when you started the drug | Confirm you meet a Bridge tier; have your prescriber submit on/after July 1, 2026 |
| UHC Medicare, GLP-1 for diabetes, sleep apnea, heart risk, or MASH | Regular Part D | Depends on the drug and your diagnosis | Your plan’s normal copay | UnitedHealthcare / OptumRx | Getting routed as “weight loss” when a covered medical reason fits better | Check your drug list and the indication-specific approval |
| UHC Medicaid / Community Plan | Your state’s Medicaid + BALANCE if your state opts in | Mounjaro, Ozempic, Rybelsus, Wegovy, Zepbound KwikPen, Foundayo | State-specific; not guaranteed | Your state Medicaid program / UHC Community Plan | Assuming “Medicaid” means automatic coverage when your state hasn’t joined | Check your state’s GLP-1 rules and prior authorization |
| UHC commercial / employer WITH weight-loss coverage | UHC commercial prior authorization | Wegovy (injection/tablet), Zepbound, Saxenda, and others | Your plan copay (often a high specialty tier) | UnitedHealthcare / OptumRx | A vague “tried diet and exercise” note instead of a documented program | Confirm coverage, then submit a complete prior authorization |
| UHC commercial / employer WITHOUT weight-loss coverage | A covered medical reason, an appeal, or cash-pay | Wegovy for heart risk or MASH; Zepbound for sleep apnea | Plan copay or cash | UHC (a different policy) | Treating a flat plan exclusion like a fixable paperwork denial | Get the exact denial reason before you do anything else |
| Denied, or honestly not sure | Figure out the lane first | Depends | Varies | Depends | Chasing the wrong fix and losing weeks | Pull your denial reason, then use the matching quiz |
Sources: Medicare Bridge rows — CMS Medicare GLP-1 Bridge and its beneficiary details. Medicaid row — CMS BALANCE Model and KFF.
Our read: For most working-age UnitedHealthcare members on a commercial or employer plan, BALANCE changes nothing — your fastest win is checking what your plan already covers and getting a clean prior authorization through. For UHC Medicare members, the real near-term event is the July 2026 Bridge, not BALANCE.
Find your UnitedHealthcare coverage lane — tell us your plan type, your drug, and your reason for treatment, and our free matching quiz shows whether the Bridge, BALANCE, commercial prior authorization, Medicaid, an appeal, or cash-pay is your next step before you spend an afternoon on hold.
Find my coverage lane →Is the BALANCE Model even a UnitedHealthcare program?
No. BALANCE — which stands for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth — is a voluntary model run by CMS, the federal agency over Medicare and Medicaid. It lowers GLP-1 prices for the state Medicaid and Medicare Part D plans that choose to join, though the Medicare side has been delayed. It is not a UnitedHealthcare benefit. UnitedHealthcare may take part in pieces of it, but BALANCE itself is a government program.
Here’s where the confusion comes from. Three different things landed in the news around the same time, and they blur together:
| Who runs it | Who it covers | Your cost | |
|---|---|---|---|
| BALANCE Model | CMS (federal) | Medicaid and, later, Medicare Part D plans that opt in | Negotiated lower prices; varies by program |
| Medicare GLP-1 Bridge | CMS, through a central processor (Humana) | Eligible Medicare Part D members | $50/month if eligible |
| UHC commercial coverage | UnitedHealthcare / OptumRx | Employer plans that bought the weight-loss benefit | Your plan’s copay |
Here’s the straight talk: If you have a UnitedHealthcare commercial or employer plan, the BALANCE Model and the federal price cut will most likely change nothing for you. BALANCE is a Medicare and Medicaid program. We’d rather tell you that now than let you wait around for a discount that was never headed to your plan. The good news: you almost certainly have a faster path anyway — the coverage your plan already offers.
For the full federal picture — the BALANCE timeline, why Part D got pushed, and what happens in 2028 — see our deep dive: CMS BALANCE Model GLP-1 Explained.
Does UnitedHealthcare take part in BALANCE and the Medicare GLP-1 Bridge?
UnitedHealthcare has said it will take part in the Medicare GLP-1 Bridge, which begins July 2026. It has not committed to full BALANCE coverage for its Part D plans. And the wider BALANCE rollout for Medicare Part D has been pushed back — it didn’t launch as planned for 2027, and is now pointed at 2028 at the earliest.
On UnitedHealth Group’s April 2026 earnings call, the company’s head of government programs said UHC is in active talks with CMS and wants to “find a path to yes” on BALANCE over time, but flagged “notable challenges and outstanding questions” with how the model is currently built. In the same breath, he confirmed UHC will participate in the Medicare GLP-1 Bridge (Becker’s).
Two things make this less scary than it sounds:
- The Bridge doesn’t actually hinge on UHC saying yes. CMS runs the Bridge outside the normal Part D system. Your Part D plan doesn’t carry the cost and doesn’t have to opt in — CMS pays pharmacies through its own central processor (CMS). So if you’re an eligible UHC Medicare member, you can use the Bridge in July 2026 no matter what UnitedHealthcare decides about BALANCE.
- BALANCE for Part D slipped to 2028. CMS planned a January 2027 Part D launch, but it didn’t move forward on that timeline. KFF reports the Part D piece is now pending for 2028, while the Medicaid side moves in 2026 (KFF).
Translation for you: don’t wait on a UHC press release. The question that changes your outcome isn’t “does UnitedHealthcare like BALANCE?” It’s “which lane fits my card, my drug, my diagnosis, and my date?” That’s what the rest of this page answers.
How the Medicare GLP-1 Bridge works for UnitedHealthcare Medicare members
The Medicare GLP-1 Bridge is a CMS pilot running through (CMS). Eligible Medicare Part D members — including UnitedHealthcare Medicare Advantage plans that include Part D drug coverage — can get Wegovy, the Zepbound KwikPen, or Foundayo for weight loss at a flat $50 copay. CMS runs it through a central processor (Humana), so your UHC plan isn’t the one approving or paying.
For most of the last two decades, Medicare simply would not cover a GLP-1 used only for weight loss. The Bridge changes that — at least temporarily.
Who qualifies for the Bridge
You have to be enrolled in a Medicare Part D plan, be 18 or older, and meet one of three clinical tiers. A lot of pages get these wrong by smashing the tiers together:
| Tier | You qualify if you’re 18+ and… |
|---|---|
| 1 | Your BMI is 35 or higher |
| 2 | Your BMI is 30 or higher and you have heart failure with preserved ejection fraction (HFpEF), uncontrolled high blood pressure (over 140 systolic or 90 diastolic while on two or more blood-pressure medicines), or chronic kidney disease at stage 3a or worse |
| 3 | Your BMI is 27 or higher and you have prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease (poor circulation in the limbs) |
Source: CMS Medicare GLP-1 Bridge beneficiary details.
The detail that trips people up: Your BMI is measured at the time you started the medication, not today. If you began a GLP-1 in 2024 with a BMI of 37 and you’re now at 34 because the drug is working, you still qualify. So if your doctor’s note only lists your current weight, the request can stall. Ask them to document your weight when therapy began.
Bridge paperwork checklist
Bring this to your prescriber appointment:
- Your BMI and weight when you started therapy (or want to start)
- The qualifying condition that puts you in a tier, documented in your chart
- The exact drug and form (for Zepbound, it’s the KwikPen only)
- A note that you’re combining the medicine with ongoing nutrition and activity changes
- Your Medicare Part D plan details
What you’d pay — and the fine print that bites
Eligible members pay a flat $50 a month, no matter where you are in your Part D benefit. CMS gets the net price down to $245 per month through manufacturer rebates. But two catches matter:
- That $50 does not count toward your Part D deductible (up to $615 in 2026).
- It does not count toward your annual Part D out-of-pocket cap ($2,100 in 2026, after which your other covered drugs are essentially free).
Because the Bridge sits outside normal Part D, your GLP-1 spending doesn’t help you hit that cap. For someone on several pricey drugs, that’s real money.
Timing
Your doctor can’t submit a Bridge request before July 1, 2026 — CMS won’t process them early. You don’t register or opt in yourself; your prescriber sends the prior authorization and prescription to CMS’s central processor.
Check your Bridge eligibility
Our free, plain-English Medicare GLP-1 Bridge eligibility quiz walks you through the tiers and tells you exactly what to document before July 1, 2026.
Check my Bridge eligibility →Which GLP-1 drugs are actually covered under the Bridge
The Bridge covers Wegovy (both the injection and the oral tablet), the Zepbound KwikPen, and Foundayo. It does not cover Zepbound single-dose vials or single-dose pens. Ozempic and Mounjaro aren’t on the Bridge weight-loss list at all.
The form matters more than people expect. Here’s the full list:
| Drug | Bridge status | The catch |
|---|---|---|
| Wegovy (semaglutide) — injection | Covered | — |
| Wegovy — oral tablet | Covered | — |
| Foundayo (orforglipron) — FDA-approved April 1, 2026 | Covered (all forms) | — |
| Zepbound (tirzepatide) — KwikPen | Covered | Only the KwikPen device |
| Zepbound — single-dose vials | Not covered | Including the cheaper LillyDirect vials |
| Zepbound — single-dose pens | Not covered | — |
| Ozempic (semaglutide) | Not a Bridge weight-loss drug | Still covered under regular Part D for type 2 diabetes |
| Mounjaro (tirzepatide) | Not a Bridge weight-loss drug | Still covered under regular Part D for diabetes |
Source: CMS Medicare GLP-1 Bridge. Foundayo approval: FDA.
Common question: “Ozempic and Wegovy are the same active ingredient — can I get Ozempic through the Bridge?” No. Both are semaglutide, but they’re different FDA-approved products with different approved uses. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management. The Bridge follows the approved use, so weight-loss access means Wegovy, not Ozempic.
What if your UHC Medicare GLP-1 is for diabetes, sleep apnea, heart risk, or MASH?
Those uses don’t go through the Bridge. They go through your regular UnitedHealthcare Part D coverage. The Bridge is only for weight management. If you have a separate, FDA-approved medical reason, the same drug runs through your normal plan with normal rules — sometimes with better coverage than the weight-loss path.
This is the “same drug, different lane” rule, and it can work in your favor:
- Type 2 diabetes. Ozempic, Mounjaro, and Rybelsus are diabetes drugs first. If that’s your reason, the question is whether your UHC Part D plan covers them on its formulary — not Bridge eligibility. See our guide on does UnitedHealthcare cover Mounjaro.
- Obstructive sleep apnea. Zepbound is FDA-approved for moderate-to-severe sleep apnea in adults with obesity. CMS treats that as a regular Part D use, not a Bridge use.
- Heart risk. Wegovy is FDA-approved to reduce the risk of heart attack and stroke in certain adults with established heart disease. That’s a regular Part D lane, not the Bridge.
- MASH. A serious fatty-liver disease (the newer name for NASH). Some GLP-1 coverage pathways now address it.
Because a drug used for a covered medical reason can sometimes be approved even when “weight loss only” is restricted — talk to your doctor about whether one of these genuinely fits your health history, not as a workaround, but because the right reason can unlock the right lane.
What the BALANCE Model means for UnitedHealthcare Medicaid (Community Plan) members
For Medicaid, BALANCE is the program that matters most in 2026 — but coverage is not automatic. It depends on whether your state’s Medicaid agency joins, whether your specific drug is included, and your state’s prior authorization rules. And some states are actually cutting GLP-1 weight-loss coverage even as the federal program expands.
If you have UnitedHealthcare Community Plan, that’s UHC running your state’s Medicaid benefit. Whether BALANCE helps you comes down to your state, not UHC:
- Did your state opt in? States can join BALANCE on a rolling basis through 2026 (KFF). Some will join early, some late, some not at all.
- Is your drug on the list? CMS lists all forms of Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen, and Foundayo as BALANCE drugs — but your state still sets coverage and prior authorization rules.
- Coverage can shrink, too. For example, UnitedHealthcare Community Plan of Massachusetts will stop covering weight-loss and obesity drugs starting to line up with MassHealth, though Medicare-covered conditions may still have a pathway (UnitedHealthcare notice).
| State | UHC Community Plan weight-loss GLP-1 status | Effective | Source |
|---|---|---|---|
| Massachusetts (MassHealth) | Stopping coverage of weight-loss/obesity drugs | UnitedHealthcare provider notice |
That’s one example, not the whole map — coverage varies a lot by state and changes often.
How UnitedHealthcare commercial and employer plans cover Wegovy, Zepbound, and other GLP-1s
This is the real lane for most working-age UHC members — and it has nothing to do with BALANCE. Whether your job-based UnitedHealthcare plan covers a weight-loss GLP-1 depends on whether your employer bought that benefit. Where it’s covered, you’ll need prior authorization, usually a BMI of 30 or higher (or 27-plus with a weight-related condition), and proof of a real lifestyle effort.
UnitedHealthcare’s own commercial pharmacy policy is blunt about this: the weight-loss drug program only applies to plans where the employer or client elected weight-loss medication coverage (UnitedHealthcare). In plain terms: two coworkers can both have “UnitedHealthcare” on the card and get opposite answers, because their employers made different choices.
Where coverage exists, here’s what the policy actually requires:
- A qualifying BMI — commonly 30 or higher, or 27 or higher with a weight-related condition like high blood pressure, high cholesterol, type 2 diabetes, heart disease, or sleep apnea.
- A documented lifestyle effort. OptumRx is stricter than most. A one-line “patient tried diet and exercise” is weaker than a specific, documented program.
- Approval windows. UHC’s policy approves Wegovy for about 5 months initially and Zepbound for about 6 months. To renew, you generally need to show at least 5% weight loss from your starting weight plus ongoing lifestyle work.
- Coaching strings. Through its Total Weight Support program, some UHC employer plans now require you to take part in a weight-management coaching program to keep your medication covered.
The prior-authorization checklist
The fastest way to get approved is to walk in with the evidence already organized:
| Bring this | Why it matters |
|---|---|
| Confirmation your employer covers weight-loss drugs | If they didn’t buy the benefit, it’s an exclusion — a different problem |
| Your BMI and weight when you started (or want to start) | Needed for the initial approval |
| Your current weight | Needed to renew (the 5% rule) |
| Your diagnoses and weight-related conditions | May unlock the lower BMI-27 pathway |
| A documented lifestyle program, not a vague mention | The avoidable gap that stalls otherwise-clean requests |
| Your exact denial reason, if you’ve been denied | Tells you whether to appeal, fix paperwork, or look elsewhere |
Check what your UHC commercial plan covers
Ro offers a free GLP-1 Insurance Coverage Checker — you enter your plan details, Ro checks your coverage and estimates your out-of-pocket cost, and if you need prior authorization, its concierge handles the paperwork. New accounts also get a $50 credit. This works for commercial, employer, and federal-employee (FEHB) plans — Ro can’t coordinate coverage for Medicare, Medicaid, TRICARE, or VA.
Check what my UHC plan covers → (sponsored affiliate link, opens in a new tab)Already know your plan type and just want to compare where to go? See our guide to GLP-1 providers that accept UnitedHealthcare.
What if your UnitedHealthcare plan won’t cover weight-loss drugs at all?
If your plan flat-out excludes weight-loss drugs, BALANCE and the Bridge probably won’t change that for a commercial plan. But you still have three honest paths: a covered medical reason, an appeal with the right documentation, or a transparent cash-pay route to an FDA-approved brand-name GLP-1.
First, figure out why you were denied — because the fix is different each time. Was it a true plan exclusion (your employer doesn’t cover the category), a paperwork problem (missing BMI or lifestyle documentation), or the wrong reason (submitted as weight loss when a medical reason fits)?
Not sure what your denial letter is really saying? Our free quiz helps you tell a flat plan exclusion from a fixable paperwork denial — and points you to the right next move.
Decode my denial →Path 1 — A covered medical reason
UnitedHealthcare keeps separate approval pathways for GLP-1s used for non-weight-loss reasons, even when weight loss is excluded — including Wegovy for cardiovascular risk reduction and for MASH, and Zepbound for obstructive sleep apnea. If one of these genuinely describes you, ask your doctor to pursue that pathway instead.
Path 2 — Appeal
If the denial was about documentation, a denial isn’t always the end. You generally have about 180 days from the denial to file an internal appeal — but check your denial letter for your exact deadline (HealthCare.gov). Bring your BMI proof, your condition documentation, and a letter of medical necessity from your prescriber; your doctor can also request a peer-to-peer review with the plan’s medical director.
Path 3 — Cash-pay, done right
If you’re truly excluded and don’t want to wait, the federal price deal has pulled cash prices down hard from the old four-figure list prices. Here’s the honest landscape:
| How you’re paying | What it runs per month | Who it’s for |
|---|---|---|
| Medicare GLP-1 Bridge | ~$50 copay | UHC Medicare members who qualify |
| TrumpRx / LillyDirect / NovoCare (cash) | Oral starts ~$149; injectable Wegovy/Ozempic ~$350 (start $199); Zepbound ~$346 (start $299); Zepbound KwikPen up to $699 | Cash payers not on Medicare, Medicaid, TRICARE, or VA |
| UHC commercial with prior authorization | Your plan copay (often a specialty tier) | Members on a covering plan |
| No coverage, full list price | Roughly $1,000+ | Almost nobody needs to — check the routes above first |
Sources: AMCP, AJMC, AARP; manufacturer-savings limits — manufacturer terms. Prices change; verify before relying on them.
Important: If you’re on Medicare, Medicaid, TRICARE, or the VA, you generally cannot use the manufacturers’ cash-savings offers — even if you choose to pay cash. That rule surprises people, so we’re saying it plainly.
See FDA-approved GLP-1 options at today’s prices
Ro lists FDA-approved options including Wegovy, Zepbound, and Foundayo — starting at $149/month for lower-dose pill options. The Ro Body membership starts at $39 for the first month, then $149/month, or as low as $74/month on an annual plan. Cash-pay is open to commercial and to Medicare and TRICARE members; Medicaid and VA members aren’t eligible.
See FDA-approved GLP-1 options → (sponsored affiliate link, opens in a new tab)Why was UnitedHealthcare cautious about BALANCE — and what that means for you
UnitedHealthcare signaled it wants to expand access but raised concerns about how BALANCE is structured, and the wider Part D launch got delayed. The practical takeaway for you is simple: don’t wait for a perfect program. Act on the lane that already fits your plan.
It’s reasonable for a giant insurer to be careful with a brand-new federal model that’s still being finalized — the cost math, the rules, and the timeline have all moved. But you don’t have to wait for that to settle. The Bridge runs on its own track. Your commercial coverage is available now. Your covered-reason pathways exist today.
So instead of refreshing the news, ask the only question that changes your outcome: which lane fits my card, my drug, my diagnosis, and my date — and what’s the next step in that lane?
What could change after 2027?
The Medicare GLP-1 Bridge is temporary — it ends . If a longer-term program (BALANCE in Part D, now pointed at 2028) doesn’t launch and your plan doesn’t pick up coverage, eligible members could face uncertainty in 2028. Plan ahead so you’re not caught off guard.
KFF lays out the risk clearly: you could have $50 GLP-1 coverage through the Bridge in late 2026 and 2027, then lose it in 2028 if BALANCE Part D or another pathway isn’t in place (KFF). What you can do:
- Save every approval letter and your weight history.
- Keep documentation of any qualifying conditions current.
- Ask your plan how it will handle continuation therapy.
- Re-check your options during Medicare open enrollment in fall 2027.
- Watch for CMS updates — we update this page when the rules move.
What to ask your doctor or UnitedHealthcare before July 1, 2026
Your goal is to avoid a generic GLP-1 request that gets denied or routed to the wrong lane. Walk in knowing your plan type, your reason for the drug, your BMI history, your starting and current weight, the exact drug and form, and your denial reason if you have one.
Ask UnitedHealthcare (or check your member account):
- Is my coverage Medicare, commercial, employer-sponsored, or Medicaid?
- Is this drug covered under my pharmacy benefit, my medical benefit, or not at all?
- If I was denied, is it a plan exclusion or a prior authorization denial?
- Is there a specific prior authorization form, and does my plan require step therapy or a coaching program?
Ask your prescriber:
- What was my BMI and weight when I started (or want to start) therapy?
- What diagnosis supports the request?
- Are we submitting through the Bridge, regular Part D, commercial prior authorization, Medicaid, or an appeal?
- Based on my reason, should this be Wegovy, Zepbound, Foundayo, Ozempic, or Mounjaro?
- Do we have documentation of a lifestyle program?
If you’ve already been denied, pull together:
The denial letter and reason code, a copy of the prior authorization form, your starting weight and BMI, your diagnosis list, your prescriber’s notes, a screenshot of your plan’s formulary, and your appeal deadline.
What we actually verified
We verified this page against CMS’s BALANCE Model and Medicare GLP-1 Bridge pages, KFF’s policy analysis, the FDA’s Foundayo approval, UnitedHealthcare’s own commercial and Medicaid policies, and recent payer reporting. We did not verify any individual’s benefits — your actual coverage depends on your plan documents, your formulary, your employer’s choices, your state’s Medicaid participation, and clinical review.
| What we checked | What it confirmed | Verified |
|---|---|---|
| CMS Medicare GLP-1 Bridge (FAQ + beneficiary details) | Bridge dates (July 1, 2026 – Dec 31, 2027), $50 copay, three eligibility tiers, drug list (Zepbound KwikPen only), central processor | |
| CMS BALANCE Model pages | Voluntary model, Medicaid + Part D scope, drug list, Medicaid timing in 2026 | |
| KFF BALANCE/Bridge analysis | Part D delay (pending 2028), Bridge as the 2026–2027 path, post-2027 uncertainty | |
| FDA | Foundayo (orforglipron) approved April 1, 2026 | |
| UnitedHealthcare commercial weight-loss policy | Employer-elected coverage, BMI criteria, 5-month/6-month approvals, 5% renewal rule | |
| UnitedHealthcare Massachusetts Medicaid notice | Weight-loss/obesity drug coverage ending July 1, 2026 | |
| Payer reporting (UHG April 2026 earnings) | UHC will join the Bridge; BALANCE participation still being decided | |
| Ro coverage/pricing pages | Cash prices, the free coverage checker, and government-plan limits |
UnitedHealthcare BALANCE Model GLP-1 — FAQ
Is UnitedHealthcare participating in the Medicare GLP-1 Bridge?
UnitedHealthcare has said it will take part in the Medicare GLP-1 Bridge beginning July 2026. CMS runs the Bridge outside the normal Part D system, so eligible Part D members can access Bridge drugs whether or not their plan opts in.
Is UnitedHealthcare participating in the BALANCE Model?
As of late April 2026, UnitedHealthcare was still deciding, citing concerns with the model’s structure. The broader BALANCE rollout for Medicare Part D was delayed and is now pointed at 2028, while the Medicaid side moves in 2026.
Does UnitedHealthcare cover Wegovy for weight loss?
It depends on your plan. Commercial and employer plans cover it only if the employer elected weight-loss drug coverage and you meet the prior authorization criteria. UHC Medicare weight-loss use runs through the Medicare GLP-1 Bridge. Certain medical reasons may qualify under regular Part D or a separate pathway.
Does UnitedHealthcare cover Zepbound for sleep apnea?
UnitedHealthcare keeps a separate approval pathway for Zepbound for obstructive sleep apnea. For Medicare, sleep apnea is handled as a regular Part D use rather than a Bridge weight-loss use.
What does the $50 Medicare GLP-1 copay mean exactly?
Eligible Bridge members pay a flat $50 per month, no matter where they are in the Part D benefit. The deductible does not apply, and that $50 does not count toward your annual Part D out-of-pocket cap ($2,100 in 2026).
Does the Bridge cover Ozempic or Mounjaro for weight loss?
No. The Bridge weight-loss drug list is Wegovy (injection and tablet), the Zepbound KwikPen, and Foundayo. Ozempic and Mounjaro remain on regular Part D for type 2 diabetes.
Does BALANCE cover Ozempic and Mounjaro?
CMS lists all formulations of Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen, and Foundayo as BALANCE drugs. But Medicaid access depends on your state joining, your drug being covered, and prior authorization rules.
Can I apply for the Bridge before July 1, 2026?
No. CMS will not accept or process Bridge requests before July 1, 2026. You can prepare by confirming you meet an eligibility tier and documenting your BMI at the time you started therapy.
What happens when the Medicare GLP-1 Bridge ends?
The Bridge runs through December 31, 2027. After that, coverage depends on whether BALANCE launches in Part D (pointed at 2028) or your plan adds coverage. Save your records and re-check during open enrollment in fall 2027.
Should I use telehealth if UnitedHealthcare denies me?
Maybe — but first find out why you were denied. A plan exclusion, a paperwork problem, and a wrong-reason denial each need a different fix. Once you know your lane, a commercial coverage check or an FDA-approved cash-pay route can make sense.
Still not sure which GLP-1 program is right for you?
Our free 60-second matching quiz maps the BALANCE Model, the Medicare GLP-1 Bridge, and your UnitedHealthcare plan’s own rules to your exact situation — and hands you a clear next step.
Start the quiz →Sources
- CMS — Medicare GLP-1 Bridge and Information for Medicare Beneficiaries — Bridge dates, $50 copay, eligibility tiers, drug list, central processor, outside-Part-D structure.
- CMS — BALANCE Model — voluntary model, Medicaid/Part D scope, drug list, Medicaid timing.
- KFF — What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — Part D delay pending 2028, Bridge as the 2026–2027 path, post-2027 uncertainty, $245 net price.
- FDA — Foundayo (orforglipron) approval, April 1, 2026.
- Becker’s Payer Issues — UnitedHealthcare eyes CMS’ BALANCE GLP-1 model (Apr 21, 2026) — UHG earnings call; UHC will join the Bridge; BALANCE undecided.
- UnitedHealthcare — commercial Weight Loss/Appetite Suppression prior authorization policy — employer-elected coverage, BMI criteria, 5-month/6-month approvals, 5% renewal, covered-reason pathways.
- UnitedHealthcare — Massachusetts Medicaid weight loss and obesity drug coverage update — coverage ending July 1, 2026.
- HealthCare.gov — internal appeals — 180-day appeal window.
- AMCP / AJMC / AARP / CBS (2025–2026) — most-favored-nation deal pricing; Medicare/Medicaid/TRICARE/VA ineligible for manufacturer cash offers.
Last verified: . Next verification scheduled July 1, 2026 (Bridge launch).